PDCD1 and neoplasm: A high TMB is generally considered to be a preexisting adaptive immune response to the tumor, and patients with a high TMB who received PD-1 blocking immunotherapy showed an improved response and enhanced clinical efficacy compared to patients with a moderate or low TMB (Hellmann et al., 2018).